A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with 18F-DCFPyL in Prostate Cancer Patients …
… tomography to stage men with high-risk prostate cancer for nodal or distant metastases,
and reliably detect sites of disease in men with suspected metastatic prostate cancer. …
and reliably detect sites of disease in men with suspected metastatic prostate cancer. …
[HTML][HTML] Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancer
… Therefore, the upregulated levels of circulating miR-132 in CRPC patients with poorer
outcome in our study are unlikely to be derived from prostate cancer cells. Instead, miR-132 may …
outcome in our study are unlikely to be derived from prostate cancer cells. Instead, miR-132 may …
Activity of second‐line chemotherapy in docetaxel‐refractory hormone‐refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone …
JE Rosenberg, VK Weinberg, WK Kelly… - Cancer …, 2007 - Wiley Online Library
… study was not designed to compare the 2 regimens, the levels of activity in this study appear
similar between the 2 … by PSA declines and objective tumor responses contrasts with results …
similar between the 2 … by PSA declines and objective tumor responses contrasts with results …
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
… phase 1–2 study was undertaken in five US centres in 140 patients. Patients with progressive,
metastatic, castration-resistant prostate cancer … data from phase 2 clinical trials of prostate, …
metastatic, castration-resistant prostate cancer … data from phase 2 clinical trials of prostate, …
… of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover …
DJ Khalaf, M Annala, S Taavitsainen, DL Finch… - The Lancet …, 2019 - thelancet.com
… same disease settings in the phase 3 AFFIRM and PREVAIL studies, and improved
progression-… in two randomised phase 2 studies. In the randomised PLATO study, patients …
progression-… in two randomised phase 2 studies. In the randomised PLATO study, patients …
A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate‐resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006
…, EJ Small, Cancer and Leukemia Group B - Cancer, 2011 - Wiley Online Library
… In summary, the current phase 2 trial has demonstrated that the addition of VEGF blockade
with bevacizumab to a docetaxel-based regimen for the treatment of patients with metastatic …
with bevacizumab to a docetaxel-based regimen for the treatment of patients with metastatic …
Magnetic resonance-guided stereotactic radiotherapy for localized prostate cancer: final results on patient-reported outcomes of a prospective phase 2 study
SU Tetar, AME Bruynzeel, SS Oei, S Senan… - European Urology …, 2021 - Elsevier
… In 2016, we activated a prospective phase 2 study of stereotactic MRgRT in patients with
localized PC and specifically investigated PROMs during the 1st year following treatment. The …
localized PC and specifically investigated PROMs during the 1st year following treatment. The …
… safety of glucocorticoid regimens in combination with abiraterone acetate for metastatic castration-resistant prostate cancer: a randomized, open-label phase 2 study
… -label, phase 2 randomized clinical trial, the 164 men with metastatic castration-resistant
prostate cancer treated … Overall, the observations of our phase 2 trial require further validation. …
prostate cancer treated … Overall, the observations of our phase 2 trial require further validation. …
… (APC8015, Provenge®) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen‐independent prostate cancer: A phase 2 trial
PA Burch, GA Croghan, DA Gastineau, LA Jones… - … Prostate, 2004 - Wiley Online Library
… This study demonstrates a definite clinical response of androgen-independent prostate
cancer to APC immunotherapy. Currently we are studying this mode of therapy in Phase 3 trials. …
cancer to APC immunotherapy. Currently we are studying this mode of therapy in Phase 3 trials. …
Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study
BA Teply, H Wang, B Luber, R Sullivan, I Rifkind… - The Lancet …, 2018 - thelancet.com
… pilot study with BAT, we sought to test BAT in patients with metastatic castration-resistant
prostate cancer who … To test these hypotheses, we did a phase 2 trial of BAT and subsequent …
prostate cancer who … To test these hypotheses, we did a phase 2 trial of BAT and subsequent …